Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Iker Huerga, CEO of Pathos AI

“Neurological diseases demand more than any one company can bring on its own: the best longitudinal data, AI that can reason over it at scale, and the drug development expertise to turn insight into medicines.”

Iker Huerga, CEO of Pathos AI

“Intelligence alone does not bring a therapy to market. These collaborations bring all three together. We are thrilled to deepen our work with Tempus and proud to have BMS leading our Series E as we build a self-learning drug development system designed to adapt clinical trials and improve the likelihood of success.”

Simon Davies, SVP, Head of Data and Quantitative Sciences, Bristol Myers Squibb

“AI has the greatest potential when it is grounded in high-quality data and applied by scientists with deep understanding of diseases and drug development.”

Simon Davies, SVP, Head of Data and Quantitative Sciences, Bristol Myers Squibb

“Our investment in Pathos reflects our commitment to applying advanced AI and data science across research and development to accelerate innovation for patients. By combining AI-driven insights with our neuroscience expertise, we hope to deepen our understanding of disease progression, improve clinical-trial design and ultimately advance new treatment options. Collaborating with Pathos and Tempus allows us to interrogate Alzheimer’s and other neurological diseases at scale, strengthening our pipeline and advancing precision medicine for patients in need.”

Eric Lefkofsky, Founder and CEO of Tempus

“Making meaningful progress against a disease as devastating as Alzheimer’s requires unprecedented data scale and computing power.”

Eric Lefkofsky, Founder and CEO of Tempus

“These collaborations unite BMS’s deep expertise, Pathos’s drug development agentic AI and Tempus’ data infrastructure. Together, we have a unique opportunity to uncover novel insights and accelerate much-needed treatments for Alzheimer’s patients.”